Livzon Group ranked 25th in the "2023 Annual Top 100 Pharmaceutical Industry in China".

Recently, the 2024 (41st) National Pharmaceutical Industry Information Annual Conference and the release conference of the 2023 China Pharmaceutical Industry Top 100 List, hosted by the China Pharmaceutical Industry Information Center, was held in Chengdu. The conference released the highly anticipated "2023 China Pharmaceutical Industry Top 100 List," with Livzon Pharmaceutical Group ranking 25th.

The "China Pharmaceutical Industry Top 100 List" reflects the operational status of the Chinese pharmaceutical industry and is recognized as an authoritative list in the Chinese pharmaceutical sector. Since the first conference was held in 1959, the National Pharmaceutical Industry Information Annual Conference has successfully held 41 sessions. This year's conference, themed "Perseverance, Innovation, and a Bright Future," gathered representatives from government, industry, academia, research, and medicine, focusing on cutting-edge industrial policies and promoting the deep integration of the pharmaceutical industry with the entire innovation ecosystem.

In recent years, Livzon Pharmaceutical Group has adhered to a development driven by research and innovation, actively responding to industry and market challenges, deeply focusing on unmet clinical needs, and accelerating the progress of research and development projects in core areas such as gastrointestinal, neuropsychiatric, assisted reproduction, metabolism, anti-tumor, and anti-infection. At the same time, it has increased efforts in business expansion, achieving new progress in multiple BD projects, laying a solid foundation for high-quality sustainable development.